Science is at the heart of everything we do.

Ground-breaking science

Publications

Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement.

View our publications
Corporate Press Release

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Corporate Press Release

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

Our science

At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.

Find out more

Career opportunities

Three

strategic science centres

Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries

Find our about our science

Our focus areas

Cardiovascular and Metabolic diseases

Oncology

Respiratory

Inflammation and autoimmunity

Neuroscience

Infection and Vaccines

AstraZeneca job search

At AstraZeneca we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.

Search for a job now

Start a career that will help improve life for millions.

Learn more about our School/College Student, Undergraduate, Graduate and Post Doctorate programmes with us in our Early Careers page.

Find your early career now

Working at AstraZeneca

We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. Find out more about our teams and the work they do.

Find out more on the careers section

To partner with AstraZeneca

Partnering with us

We partner with like-minded organisations and pursue a range of different types of opportunities that are aligned with our portfolio and areas of expertise.

Learn more about our areas of interest
Corporate Press Release

AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline

Corporate Press Release

Updated overall survival data for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer presented at AACR

Investor information

Financial calendar

Find all the latest dates for ex-dividends, investor roadshows and more

See all key dates
Corporate Press Release

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Corporate Press Release

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer